# Core C: Special Assessment of Graft Function Post Transplant

> **NIH NIH P01** · SLOAN-KETTERING INST CAN RESEARCH · 2020 · $267,354

## Abstract

Abstract
Allogeneic hematopoietic cell transplantation (Allo-HCT) is a well established curative approach for a variety of
malignant and nonmalignant hematologic disorders. Recurrence of primary disease, graft-versus-host disease
(GVHD), infection, and regimen related toxicity remain the primary causes of transplant failure. The tempo and
quality of hematopoietic engraftment and immunologic reconstitution significantly influence morbidity and
mortality following Allo-HCT. Adult recipients of an Allo-HCT experience deficiencies in their B and T cell
reconstitution, which can persist for more than a year, and are associated with an increased risk of infections,
relapse of malignancy, and the development of secondary malignancies. The purpose of Core C is to define
hematopoietic cell grafts and adoptively transferred T-cell populations and their function prior to and following
transplantation. The core will characterize allografts and monitor the effects of stem cell source, donor type,
use of T cell depletion, immunomodulatory agents and/ or adoptive immunotherapy, as well as development of
GVHD on the kinetics and quality of immune reconstitution, donor chimerism, and relapsed disease following
Allo-HCT. The Specific Aims of Core C are: 1) To characterize allografts by flow cytometry, clonogenic assays,
and functional assays to predict graft outcome (Project 6); 2) To monitor the recovery of circulating T, B, and
NK populations after allo-HCT. This will include assessment of subsets of CD4 and CD8 T cells, B cells, TREC
expression, T cell responses to mitogens, alloantigens, recall and neoantigens, high-resolution quantification of
human TCR diversity using deep sequencing, monitoring of biomarkers and cytokine levels and development
of specific antibody responses following revaccination post HCT. These data will gauge the effects of α/β+ T-
lymphocyte depletion of the allograft, studies of the impact of the gut microbiome on HCT outcomes (including
viral infections, the impact of antibacterial drug selection on microbiome integrity and fecal microbiota
transplants (FMT), interactions between NK and T cells in HCT, as well as adoptive immunotherapy with CD19
CAR T cells (All Projects). 3) To monitor lineage-specific chimerism following allo-HCT. This will provide in vivo
correlates of interventional studies including α/β+ T-lymphocyte depletion of the allograft and adoptive cell
therapy, and their effects on engraftment (Project 6), reconstitution of NK cells and interactions with T cells
(Project 3), and donor-derived antigen-specific T cells and their effects on residual normal and malignant host
hematopoietic elements (Projects 4, 5 and 6). 4) To characterize adoptively transferred T cells prior to and post
infusion using multiparameter flow cytometry, functional assays, as well as high-resolution quantification of
human TCR diversity to specifically track infused cells (Projects 4, 5 and 6). 5) To centralize specimen
procurement, prioritizatio...

## Key facts

- **NIH application ID:** 9984302
- **Project number:** 5P01CA023766-40
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** MIGUEL-ANGEL PERALES
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $267,354
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9984302

## Citation

> US National Institutes of Health, RePORTER application 9984302, Core C: Special Assessment of Graft Function Post Transplant (5P01CA023766-40). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9984302. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*